Board summary
Key figures
50,265
Registered population
61.5% aged 18–64
17.7%
Aged 65+
ICB 19.0% · England 17.9%
5.8%
Ethnic minority (non-White)
2.3% Asian · England 9.6%
58.9%
In IMD quintile 1
ICB 31.9% · England 21.0%
~26,246
Core20 residents (est.)
Resident basis; registered basis ~30,712 · see page 3
8,773
Hypertension register
+4.56% in 3 yrs · England +5.60%
699
SMI register
35.7% of Knowsley (LAD)'s
1,821
COPD register
Reviews +54.65% in 3 yrs
Forecast to 2030
9,682
Hypertension patients, 2030
+909 on today
68.8%
QRISK ≥20% on statins, 2030
+3.57pp over 3 yrs
4.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Rapid three-year gains in long-term condition reviews.
Over 2023 to 2025, annual review coverage rose +54.6% in COPD to 79.2% (England 76.4%), alongside gains in heart failure (+51.4%) and asthma (+47.6%).
Unreviewed asthma cohort alongside high paediatric prescribing.
At 66.2% review coverage across 3,377 asthma patients, about 1,100 lack a recorded review, while age 5-19 prescribing is 3,415 per 1,000 (England 1,488).
Cardiovascular and SMI treatment indicators trail England.
Hypertension treated to threshold (66.9% vs 70.3% in England), QRISK >= 20% lipid therapy (61.0% vs 63.6%) and SMI BP checks (80.1% vs 83.4%).
Population, age and ethnicity
Registered patients include 10,466 children and 8,891 older adults alongside 27 catchment care homes
West Knowsley PCN serves 50,265 registered patients. Registered children aged 0-17 comprise 20.8% (10,466 patients), compared with 21.1% in Knowsley, 19.2% in the ICB, and 19.6% in England. Registered adults aged 65+ represent 17.7% (8,891 patients; England 17.9%, Knowsley 16.9%, ICB 19.0%). Census usual residents in associated areas are 94.2% White, against 95.3% in Knowsley, 93.0% in the ICB, and 81.1% in England, giving a 5.8% ethnic minority share. Resident Census geography does not represent registered patients.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Knowsley (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Knowsley LA) | 2,784 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Knowsley LA) | 1,440 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Knowsley LA) | 23.1 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 58.9% PCN-wide, spanning 40.9% to 88.6% across practices
West Knowsley PCN records an average IMD decile of 3.1, with 58.9% of registered patients in the Core20 cohort (England 21.0%, Knowsley 52.5%, ICB 31.9%). Practice deprivation spans 47.7 pp: Colby Medical Centre (88.6%) and Primrose Medical Practice (88.4%) lead in concentration, while Cornerways Medical Centre (11,659 estimated patients) and Aston Healthcare Limited (6,731 estimated patients) have the largest volumes. Weighted practice share is 61.1%, differing from the PCN rate by 2.19 percentage points. Dual allocation across high-concentration practices and high-volume lists can address distinct Core20 workload demands.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
699
SMI register
1.35% recorded prevalence
326
Learning disability register
0.63% recorded prevalence
27
Care homes, 1,196 beds
In the PCN catchment
11.5%
Provide unpaid care
Knowsley (LAD), Census 2021
The PCN records 699 severe mental illness patients (1.4% prevalence; England 1.0%, Knowsley 1.2%, ICB 1.1%) and 326 on the learning disability register (0.6%; England 0.6%, Knowsley 0.7%, ICB 0.6%). PCN catchment services contain 27 care homes with 1,196 beds, though bed capacity does not establish occupancy or registered resident counts. The severe mental illness register sits above England, so physical-health checks for this group are the larger inclusion-health workload.
Severe mental illness: physical health checks
On the SMI register (699 patients; 1.4% prevalence), 80.1% had a blood pressure check, trailing England (83.4%), despite 95.3% having BMI recorded. Prioritising blood pressure checks during routine reviews could close this cardiovascular monitoring gap.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,773
Hypertension register
+4.56%
Register growth, 3 yrs
Knowsley (LAD) +5.44% · England +5.60%
+16.59pp
BP control, under 80
≤140/90 · +9.81pp aged 80+
+909
More patients by 2030
Forecast 9,682 (18.56%)
Hypertension case-finding and control
Hypertension prevalence is 17.0% (8,773 patients), above England (15.2%), Knowsley (16.7%) and the ICB (16.8%), though the register's implied base (51,667) exceeds the 50,265 list size. Recent blood pressure monitoring reached 89.4% (England 90.0%). Despite a 3-year gain of +14.9 pp (England +2.5 pp), treatment to target sits at 66.9%, trailing England (70.3%), Knowsley (69.6%) and the ICB (69.1%). Control trails across age cohorts: under-80 control is 64.8% (England 67.8%) and aged 80+ control is 76.7% (England 81.2%). Blood pressure control trails national benchmarks across both age cohorts despite near-benchmark monitoring, prioritizing systematic medication titration and recall to close the management gap.
Lipids and statins
Lipid therapy reaches 61.0% of patients with QRISK ≥ 20%, trailing England (63.6%), Knowsley (64.0%) and the ICB (63.2%). Statin coverage in diabetes without CVD is 70.8% (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than England rates imply, indicating scope for systematic recall across primary prevention cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 110,802 | £1.70 | £1.71 | £1.86 | £188,363 |
| Cardiovascular (all), 2025 | 162,405 | £3.88 | £4.37 | £3.33 | £630,131 |
In 2026, lipid-modifying drugs cost £1.70 per item across 110,802 items, compared with £1.86 in England, £1.63 in Knowsley and £1.71 in the ICB. The PCN spent £17,728 less than at England's unit cost. Lower unit cost than England does not establish formulary efficiency, but indicates existing prescribing expenditure across high-volume lipid items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+47.64%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.20%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 3.5% (1,821 patients), above England (1.9%), though the register fell 3.7% over 2023 to 2025 (England +2.6%). Reviews reached 79.2% in COPD and 66.2% in asthma (3,377 patients; England 65.7%), leaving about 1,100 asthma patients unreviewed. Alongside this, paediatric asthma prescribing reached 3,415 items per 1,000 aged 5-19 against England's 1,488 rate. High prescribing alongside unreviewed asthma patients suggests an opportunity to audit inhaler regimens and target structured annual reviews.
Cancer register and children's immunisation
Cancer prevalence is 3.6% (1,847 patients), below England (3.8%). In Q1 2025/26, childhood immunisations trailed the 95% target: 24-month MMR1 was 72.7% (22.3 pp below target; England 88.3%) and age-5 MMR2 was 73.5% (21.5 pp below target; England 82.8%). At age 5, the MMR dose difference was 10.6 pp across the PCN. Lower uptake leaves cohorts vulnerable, making second-dose recall and outreach a critical paediatric priority.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of staged cancers in NHS Cheshire and Merseyside ICB (7,482 of 13,490) were stage 1 or 2, against England (55.3%) and 19.5 pp below the 75.0% national ambition by 2028, requiring about 2,640 extra early-stage cases annually. Known-stage share was 72.8% (13,490 of 18,522). This wider-system data was not captured at PCN level. Locally, PCN breast screening was 63.7% (England 69.9%; ICB 72.0%), and cervical screening was 65.3% (England 66.8%) after falling 5.1% over 2023 to 2025 (England -1.0%). Persistent screening shortfalls may delay early detection, making proactive recall a PCN priority.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Mersey and West Lancashire Teaching Hospitals NHS Trust met the 62-day referral to treatment standard for 78.0% of pathways (309.5 of 397), 7.0 pp below the 85.0% standard, but above England (71.2%), Liverpool University Hospitals NHS Foundation Trust (73.3%) and the ICB (76.2%), though behind North Cheshire and Mersey NHS Foundation Trust (83.7%). On the 28-day faster diagnosis standard, the trust achieved 72.4% (2,790 of 3,854) against the 75.0% standard, trailing the ICB (77.2%) and England (79.3%). These provider metrics describe wider acute performance.
| Pathways within standard (%) | Mersey and West Lancashire | Liverpool | North Cheshire and Mersey | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 72.39 | 75.47 | 80.21 | 77.25 | 79.32 |
| 31-day treatment (96%) | 95.46 | 90.51 | 98.17 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.96 | 73.26 | 83.67 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mersey and West Lancashire | Liverpool | North Cheshire and Mersey | England |
|---|---|---|---|---|
| MRI | 14.04 | 6.42 | 0.53 | 21.40 |
| CT | 13.08 | 0.71 | 2.32 | 9.92 |
| Echocardiography | 34.88 | 12.55 | 28.04 | 28.48 |
| Colonoscopy | 18.04 | 33.14 | 15.98 | 30.83 |
| Gastroscopy | 18.17 | 44.99 | 20.24 | 29.02 |
| All 15 DM01 tests | 21.17 | 11.50 | 6.34 | 23.14 |
| Community services activity | Knowsley residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 45,655 | 541,280 |
| Referrals | 8,475 | 97,150 |
| Patients with a contact | 12,490 | 146,240 |
Community services (residents of Knowsley), Jun 2026 (provisional). In Jun 2026 (provisional), community health service activity recorded across Knowsley borough residents totalled 45,655 contacts. Adults aged 65 and over accounted for 57.9% of these contacts (26,435). These figures from the Community Services Dataset reflect wider borough resident activity rather than West Knowsley PCN registered-patient contacts, highlighting substantial older-adult community demand across the borough.
Practice variation and patient experience
Patient experience varies sharply across practices, with phone access spanning 43.1 percentage points
In 2025/26, overall QOF achievement spanned from 81.9% at Hillside House Surgery to 88.7% at Primrose Medical Practice, trailing England (92.5%). All seven practices scored 15.6% in vaccination and immunisation against England's 55.2%, whereas clinical domain achievement remained resilient, reaching 89.7% to 97.7% (England 97.1%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| The | 120 | 45.0 | 77.9% | 67.8% | 92.9% |
| Primrose Medical | 138 | 88.4 | 72.1% | 76.1% | 83.3% |
| Colby | 108 | 88.6 | 84.8% | 71.2% | 82.1% |
| Hillside House | 117 | 77.4 | 69.7% | 78.0% | 78.5% |
| Cornerways | 103 | 81.6 | 41.8% | 70.1% | 75.6% |
| Roseheath Surgery | 89 | 51.7 | 52.6% | 80.7% | 66.5% |
| Aston Healthcare | 85 | 40.9 | 44.5% | 83.0% | 63.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia (+0.7%), stroke (-1.4%), and COPD (-3.7%) registers trailed England over three years
Over 2023 to 2025, relative three-year register changes trailed England in COPD (-3.7% versus +2.6% in England), dementia (+0.7% versus +6.0% in England and +11.5% in Knowsley), and stroke (-1.4% versus +2.3% in England). In contrast, PCN review completion rose over the same three-year window by +54.6% in COPD (England +2.8%) and +51.4% in heart failure (England +8.7%), lifting current heart failure reviews to 81.4% (England 78.5%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD register
Dementia register
Cervical screening
Stroke register
Breast screening (53-70)
COPD reviews
Asthma reviews
Heart failure reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Knowsley (LAD) | Asset | PCN | Knowsley (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 27 (1,196 beds) | n/a | Schools (catchment) | 110 | n/a |
| Children's centres | 11 | 15 | Places of worship | 27 | 48 |
| Libraries | 3 | 3 | Primary schools (LA maintained) | 20 | 32 |
| Primary academies | 12 | 13 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and inhaler recall
Out of 3,377 asthma register patients, 66.2% had a review (England 65.7%), leaving 1,140 (about 1,100) unreviewed, while prescribing is 3,415 items per 1,000 aged 5-19 (England 1,488). For discussion: run a structured asthma recall combining annual review templates with inhaler prescribing checks, offering after-school slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension titration and lipid recall
Hypertension treatment to target is 66.9% (England 70.3%; under-80s 64.8% vs 67.8%; 80+ 76.7% vs 81.2%) on an 8,773 register, and lipid therapy for QRISK ≥ 20% is 61.0% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
SMI physical health check completion
On the 699-patient SMI register (1.4% prevalence; 35.7% of the Knowsley register), blood pressure check completion is 80.1%, trailing England (83.4%), Knowsley (82.5%) and the ICB (81.3%), despite 95.3% BMI recording. Low cost, quick to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Dual-track Core20 allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness blood pressure recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration and recall review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation call and recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Primary care access and telephony review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension titration and lipid recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · SMI physical health check completion (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
